Integrating systemic and molecular levels to infer key drivers sustaining metabolic adaptations

PLoS Comput Biol. 2021 Jul 23;17(7):e1009234. doi: 10.1371/journal.pcbi.1009234. eCollection 2021 Jul.

Abstract

Metabolic adaptations to complex perturbations, like the response to pharmacological treatments in multifactorial diseases such as cancer, can be described through measurements of part of the fluxes and concentrations at the systemic level and individual transporter and enzyme activities at the molecular level. In the framework of Metabolic Control Analysis (MCA), ensembles of linear constraints can be built integrating these measurements at both systemic and molecular levels, which are expressed as relative differences or changes produced in the metabolic adaptation. Here, combining MCA with Linear Programming, an efficient computational strategy is developed to infer additional non-measured changes at the molecular level that are required to satisfy these constraints. An application of this strategy is illustrated by using a set of fluxes, concentrations, and differentially expressed genes that characterize the response to cyclin-dependent kinases 4 and 6 inhibition in colon cancer cells. Decreases and increases in transporter and enzyme individual activities required to reprogram the measured changes in fluxes and concentrations are compared with down-regulated and up-regulated metabolic genes to unveil those that are key molecular drivers of the metabolic response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biochemical Phenomena
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / metabolism
  • Computational Biology
  • Computer Simulation
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glycolysis
  • HCT116 Cells
  • Humans
  • Kinetics
  • Linear Models
  • Metabolic Flux Analysis / statistics & numerical data
  • Metabolic Networks and Pathways*
  • Metabolomics / statistics & numerical data
  • Models, Biological*
  • Proof of Concept Study
  • Protein Kinase Inhibitors / pharmacology
  • Systems Theory

Substances

  • Protein Kinase Inhibitors
  • CDK4 protein, human
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6

Grants and funding

MC was supported by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR; Generalitat de Catalunya) (2017SGR1033), Instituto de Salud Carlos III (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - CIBEREHD-CB17/04/00023, Instituto Nacional de Bioinformática - PT17/0009/0018), Ministerio de Economía y Competitividad (SAF2017-89673-R) and Ministerio de Ciencia e Innovación (PID2020-115051RB-I00) (Co-funded by the European Regional Development Fund - “Una manera de hacer Europa”). JTC acknowledges the support from the Ministerio de Educación y Formación Profesional (FPU14-05992). MC acknowledges the support received through the prize “ICREA Academia” for excellence in research, funded by ICREA foundation – Generalitat de Catalunya. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.